You are on page 1of 12
2) United States Patent Hildebrand US006656172B1 US 6,656,172 BL Dec. 2, 2003 a0) Patent No.: (45) Date of Patent: (54) METHOD FOR TREATING SEVERE TINNITUS (75) Inventor: Keith Robert Hildebrand, Houlton, WI (US) (73) Assignee: Medtronic, Inc., Minneapolis, MN (Us) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 ‘3 days. en @) Appl. No. 10/259,101 Sep. 27, 2002 Filed (51) Int. CL? (2) (58) AGIK 9/22; A6LB 19/00 US. Cl. (604/891.1; 128/898 Field of Search 1604)500, 28, 116, {604/891.1, 890.1, 1515 128'897-899 (56) References Cited U.S. PATENT DOCUMENTS 5,496,360) A nN 3/1996 19/1997 Howard, I Howard, Il eta Howard, Il eta Zenner t a Donovan Lenzare 0493 said 04/21 6377849 Bie OTHER PUBLICATIONS ‘42002 Lewis, JE, $.D.G, Stephens, et al. (1993). “Tinnitus and suicide.” Clin Otolaryngol 19:50-54, McFadden, D. (1982). Tinnitus: Facts, Theories, and Treat ‘ments, Washington D.C., National Academy Press, Sataloff, J, RT. Satalofl etal. (1987). “Tinnitus and vertigo in healthy senior citizens without a history of noise expo- sure,” Am J Otol 8 (2):87-89. Axelsson, A. and A. Ringdahl (1989). “Tinnitus—a study of its prevalence and characteristics.” British Journal of Audi ology 23: 53-62, ass 8 Coles, R.R.A., Thompson, et al. (1992), “Intea-tympanie injections in the ueatment of tinnitus.” Clin Otolaryngol 17(3): 240-242. Dobie, R.A. (1999), “A review of randomized clinical trials in tinnitus.” The Laryngoscope 109: 1202-1211. Lockwood, A.H., RJ. Salvi, et al. (1998), “The functional rncuroanatomy of tinnitus: Evidence for limbic system links and neural plasticity.” Neurology 50: 114-120, ‘Moller, A.R. (2001). “Symptoms and signs eaused by neural plasticity." Neurological Research 23: 565-872. Den Hartigh, 1, C. G. J. M. Hilders, et al (1993), suppression by intravenous lidocaine in celation 10 its plasma concentration.” Clin Pharmaocol & Ther 54415120) ‘Ochi, K. and J. Eggermont (1996), “Effects of salicylate on neural activity ia cat primary auditory cortex.” Hearing Research 95 (1-2): 63-76 Caspary, D.M., J. C. Milbrandt, et al. (1995), ‘Auditory Aging: Gaba Changes in the Inferior Colliculus.” Experimental Geromology 30 (3/4):349-360. MoGeer, E, G. and P. L. MeGeer (1975). “Age Changes in the Human for Some Enzymes Associated with Metabolism of the Catecholamines, Gaba and Acetycholine.” Neurobi ology of Aging. J. Ordy, Brizzee KR, New York, Plenum Pres: 287-305. Raza, A., J.C. Milbrandt, et al. (1994). “Age-Related Changes in Brainstem Auditory Neurotransmitters: Mea- sures of GABA and Acetyleboline Function.” Hear Res 77 (1-2):221-230. Tinnitus ‘Central (List continued on next page.) Primary Examiner—Sharon Kennedy (74) Attorney, Agent, or Firm—Banner & Witcof, Lid 6 ABSTRACT ‘A method for treating severe tinnitus is disclosed. The ‘method of the present invention comprises implanting catheter into a patient and administering a therapeutic agent intcatheeally into the patient's cerebrospinal fluid, 36 Claims, 5 Drawing S| US 6,656,172 BI Page 2 OTHER PUBLICATIONS Araki, 'E, H. Kato, et al. (1993). “Selective changes o! ‘neurotransmitter receptors in middle-aged gerbil brain. Neurochem Int 23(6): 541-548. Mildbrandt, J. C., R. L. Albin, etal. (1994). “Age-Related Decrease in GABAB Receptor Binding in the Fischer 344 Rat Inferior Colliculus.” Neurobiol Aging 15(6): 699-703. Moller, A. R., M. B. Moller, t al. (1992). “Some Forms of Tinoitus May Involve the Extralemniscal Auditory Path- way” Laryngoscope 102(10). 1165-1171. ‘Szezepaniak, W. S. and A. R. Moller (1995). “Effects L—Ba- ‘lofen and D-Bachlofea on the Auditory System: A Study of <-Evoked Potentials from the Inferior Colliculus in the Rat.” Ann Otol Rhinol Laryngol 104(5): 399-404, Szezepaniak, W. S. and A. R. Moller (1996). “Effects of (-) baclofen, clonazepam, and diazepam on lone exposure: ‘duced hyperexcitability of the inferior colliculus ia the rat possible therapeutic implications for pharmacological man- agement of tinnitus and hyperacusis.” Hear Res 97:46-53. Lees, A.J..C.R. Clarke, et al. (1997). “Hallucinations After Withdrawal of Baclofea.” Lancer 80163858. Zapp, J.J. (2001). “Gabapentin forthe treatment of tinnitus: Accase report." ENT-Far, Nose & Throat Journal: 114-116. Kuzniecky, R., 8. Ho, etal (2002). "Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults.” Neurology 58: 368-372. Petroll, O.A., F. Hyder, etal. (2000). “Effects of Gabapentin on Brain GABA, Homocamnosine, and Pyrrolydinone in Epilepsy Patients.” Epilepsia 41(6): 675-680. Westerberg, B. D., J. B. Roberson, et al. (1996). “A double ind placeb-controlled trial of baclofen in the treatment of | tinnitus.” Am J Otolaryngol 17: 896-903, Coffey, R- J., D. Cahill, et al. (1993). “Intrathecal baclofen for iniractable spasticity of spinal origin: results of a loag~ term multicenter study." J Neurosurg 78: 226-232. Meythaler, J. M.,S. Guin-Reafive, et al. (2001). “Continu- ously Infused Intrathecal Baclofen for Spastie/Dystonic Hempiplegia.” Arch Phys Med Rehabil 82: 155-161 Penn, R, D.,S. M Savoy, etal. (1989), “Intrathecal Baclofen for Severe’ Spinal Spastcity.” New England Journal of Medicine 320: 1571-1521 Knutson, E., U. Lindblom, et al. (1974), “Plasma and Cerebraspinal Fluid Levels of Baclofen (Lioresal) at Opti- mal Therapeutic Responses in Spastic Paresis.” Journal of the neurological Sciences 23: 473-484, Kroio, J. (1992). “Iotrathecal Drug Administration.” Clin Pharmacokinet 22(5). 319-326, Kroin, J. S. and RD. Penn (1991). Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen, Parenteral drug therapy in spasticity and parkinson’s disease. L. . a. Carnforth, Parthenon Publishing: 67-77. Muller, H., J. Zierski, et al, (1988). “Pharmacokinetics of Intrathecal Baclofen.” Local-spinal therapy of spasticity. Z J. Muller, H, Penn R.D. Berlin, Springer-Verlag: 223-2 Milbrandt, JC, Holder TM, Wilson MC, Salvi RJ, Caspary DM. “GAD levels anc! muscimol binding in rat inferior colliculus following acoustic trauma.” Flear Res (2000) Sep.; 147 (1-2):251-60. Caspary, D.M., IM. Holder, etal.“ Age-Related Changes in GABA (A) Receptor Subunit Composition and Funetion in Rat Auditory System.” Neuroscience 1999;93(1): 307-12. Milbrandt JC, Hunter C, Caspary DM. “Alterations of GABA, Receptor Subunit mRNA Levels in the Aging Fischer 344 Rat Inferior Colliculus”"J Comp Neurol (1997) Mar. 17; 379 (3):455-66. Milbrandt JC, Albin RL, Turgeon SM, Caspary DM. “GABA, Receptor Binding in the Aging Rat Inferior Col- liculus.” Neurascience (1996) Jul; 742):449-S8, Simpson, JJ. and WEE, Davies (1999), “Recent advances in the pharmacological treatment of tinnitus.” TIPS 20: 12-18. Jastreboft, PJ, W.C. Gray, etal. (1996). “Neurophysiologic eal approach to tinnitus patients.” Amer J Otol 17: 236-240. ‘Merchant, S.N. and MLV. Kirtane (1986). “Vestibular effects of intravenous lidocaine used in the treatment of tinnitus.” J Laryngol Otol 100:1249-1253, Podoshin, L., M. Fradis, etal, (1992). “Treatment of tinnitus by intratympanic installation of lignocaine (Liocaine) 2 per eat through ventilation tubes.” J Laryngol Oral 105(7):603-606. Raza, A., J.C. Mildbrandt (1994), “Age-related changes in brainstem auditory neurotransmitters: measures of GABA and acetylcholine function.” Hear Res 71(1-2): 221-230, Kaltenbach, J. A. (2000). “Neurophysiologic Mechanisms of Tinnitus.” J Am Acad Audiol 11:125-137 * cited by examiner U.S. Patent Dec. 2, 2003 Sheet 1 of 5 US 6,656,172 BL